STRATEC’S ANNUAL GENERAL MEETING APPROVES FURTHER DIVIDEND INCREASE: DISTRIBUTION RISES TO € 0.97 PER SHARE

Birkenfeld, May 17, 2023

Shareholders at today’s Annual General Meeting of STRATEC SE (Frankfurt: SBS; Prime Standard, SDAX) approved all agenda items submitted for resolution with clear majorities. As in the past three years, the Annual General Meeting was held on a virtual basis. In terms of its format, however, today’s meeting approximated very closely to that of an in-person Annual General Meeting: Shareholders had comprehensive rights to make statements, ask questions, and submit motions. They also had the opportunity to join the meeting live by video to speak during the general debate.

As proposed, STRATEC will be distributing a dividend of € 0.97 per share to its shareholders for the past 2022 financial year (previous year: € 0.95). The distribution total amounts to € 11.8 million and will be paid out to shareholders via their depositing banks on May 22, 2023. This represents the nineteenth consecutive increase in the dividend since payment of the first dividend in 2004.

Shareholders also approved the actions of the Board of Management and of the Supervisory Board and elected Ebner Stolz GmbH & Co. KG, Stuttgart, as auditor for the 2023 financial year. Furthermore, the Annual General Meeting adopted a new stock option plan and confirmed the amended remuneration system for Supervisory Board members. Shareholders also approved all other agenda items with the required majority.

Overall, 84.1 percent of the company’s share capital was represented at the virtual Annual General Meeting.

Further information about the Annual General Meeting can be found at www.stratec.com/agm, where details of voting results have also been published.

ABOUT STRATEC
STRATEC SE (www.stratec.com) designs and manufactures fully automated analyzer systems for its partners in the fields of clinical diagnostics and life sciences. Furthermore, the company offers complex consumables for diagnostic and medical applications. For its analyzer systems and consumables, STRATEC covers the entire value chain – from development to design and production through to quality assurance.

The partners market the systems, software and consumables, in general together with their own reagents, as system solutions to laboratories, blood banks and research institutes around the world. STRATEC develops its products on the basis of patented technologies.

Shares in the company (ISIN: DE000STRA555) are traded in the Prime Standard segment of the Frankfurt Stock Exchange and are listed in the SDAX select index of the German Stock Exchange.

FURTHER INFORMATION IS AVAILABLE FROM:
STRATEC SE
Jan Keppeler | Investor Relations, Sustainability & Corporate Communications
Tel: +49 7082 7916-6515
[email protected]
www.stratec.com